

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): TURPEN, et al

Serial No.: 10/602,219

Filed: 6/23/2003

Title: Production of Lysosomal Enzymes in

Plants by Transient Expression

Attorney Docket No.: LSBC-0087-CN09B

Group Art Unit:, 1652 v

Examiner:

Delia M. RAMIREZ

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants submit herewith Form 1449, which lists references that were cited in Forms 1449 and Forms 892 that were cited by or submitted to the U.S. Patent and Trademark Office in Application No. 09/993,059, filed November 13, 2001; and 09/626,127, filed July 26, 2000, which is relied upon an earlier filing date under 35 U.S.C. 120. Thus, copies of these references are not attached since they are available in the parent files. 34 CFR 1.98(d).

It is respectfully requested that the cited information on the attached Form 1449 be expressly considered during the prosecution of this application, and that the references be made record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

U.S. Patent Application No. 10/602,219 Attorney Docket No. LSBC-0087-CN09B Page 2

This Supplemental Information Disclosure Statement is being filed within three months of the U.S. filing date or before the mailing date of a first Office Action on the merits. No statement under 37 C.F.R. § 1.97(e) or fee is required.

It is requested that the information disclosed herein be made of record in this application.

I hereby certify that this Correspondence is being deposited with the United States Postal service with sufficient postage for first class mail in an envelope address to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

Date: 6 Apr (200)

Thomas Gallegos, Reg. No. 32,692

Respectfully submitted,

Thomas Gallegos, Reg. No. 32,692

Attorney for Applicant(s)

Large Scale Biology Corporation

Date: 0

Telephone No.: (707) 469-2307

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

	Substitute for form 1449A/PT	0	OIPE	//	Complete if Known		
		,		8	Application Number	10/602,219	
	INFORMATION DISC	LO\$	URE	130	Filing Date	6/23/2003	
	STATEMENT BY APP	PLI	ANT U 8 200)5 j	First Named Inventor	TURPEN	
(Use as many sheets as necessary)					Art Unit	1652	
	(Use as many sheets as no	ecess	PADEMAR'		Examiner Name	Delia M. RAMIREZ	
Sheet	1	of	3		Attorney Docket Number	LSBC-0087-CN09B	

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Document Number Number - Kind Code ² (if known)	MM-DD-YYYY Applicant of Cited Document		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
		4,921,902	5/1/1990	HALL, et al.			
		5,316,931	5/31/1994	DONSON, et al.			
		5,401,650	3/28/1995	DESNICK, et al.			
		5,356,804	10/18/1994	DESNICK, et al.			
		5,589,367	12/31/1996	DONSON, et al.			
		5,618,699	4/8/1997	HAMAMOTO, et al.			
***************************************		5,955,647	9/21/1999	FITCHEN, et al.			
······		5,977,438	11/02/1999	TURPEN, et al.			
		6,033,895	3/7/2000	GARGER, et al.			
	-	6,042,832	3/28/2000	KOPROWSKI, et al.			
		6,210,666	4/3/2001	MIYAMURA			
	<u> </u>	6,232,099	5/15/2001	CHAPMAN, et al.	the second secon		

	FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶				
		EP 0174759	3/19/1986	JAMES, et al.						
		EP 0197809	10/15/1986	DELGRANGE, et al.						
· · · · · · · · · · · · · · · · · · · 		EP 0672754	9/20/1995	HAMAMOTO, et al.						
		EP 0726312	8/14/1996	EKEZE, et al.						
		WO 92/18618	10/29/92	LOMONOSSOFF, et al.						
		WO 95/21248	8/10/1995	FITCHEN, et al.	<u> </u>	***************************************				
		WO 96/02649	2/1/1996	LOMONOSSOFF						
		WO 96/12027	4/25/1996	CHAPMAN, et al.						
		WO 96/12028	4/25/1996	TURPEN, et al.						
		WO 97/10353	3/20/1997	RADIN, et al.						
·····		WO 97/39134	10/23/1997	WILSON, et al.						
		WO 97/49425	12/31/1997	BEEKMAN, et al.						
		WO 99/46288	9/16/1999	GARGER, et al.		***************************************				

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Sı	ubstitute for form 1449	B/PT	O		Complete if Known		
				Application Number	10/602,219		
IN	IFORMATION D	ISC	LOSURE	Filing Date	6/23/2003		
	TATEMENT BY			First Named Inventor	TURPEN		
_	(use as many sheets			Group Art Unit	1652		
				Examiner Name	Delia M. RAMIREZ		
Sheet	2	of	3	Attorney Docket Number	LSBC-0087-CN09B		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		BAKER, et al., "Polyethylenimine (PEI) is a simple, inexpensive and effective reagent for condensing and linking plasmid DNA to adenovirus for gene delivery", Gene Therapy (1997) 4:773-782	
		DAWSON, et al., "A Tobacco Mosaic Virus-Hybrid Expresses and Loses an Added Gene", Virol. (1989) 172:285-292	
		DAWSON, et al., "cDNA cloning of the complete genome of tobacco mosaic virus and production of infectious transcripts", <i>Proc. Natl. Acad. Sci. USA</i> (1986) 83:1832-1836	
		DAWSON, et al., "Modifications of the tobacco mosaic virus coat protein gene affecting replication, movement, and symptomatology", Mol. Plant Pathol. (1988) 78(6):783-789	
- ntosmansinassossamuoniusius minnus		DONSON, et al., "Systemic expression of bacterial gene by a tobacco mosaic virus-based vector", <i>Proc. Natl. Acad. Sci. USA</i> (1991) 88:7204-7208	
		HAMAMOTO, et al., "A new tobacco mosaic virus vector and its use for the systemic production of angiotensin-l-converting enzyme inhibitor in transgenic tobacco and tomato", Bio/Tech. (1993) 11:930-932	
		HAYNES, et al., "Development of a genetically-engineered, candidate polio vaccine employing the self-assemblying properties of the tobacco mosaic virus coat protein", <i>Bio/Tech</i> . (1986) 4:637-641	
		JADADISH, et al., "High level production of hybrid potyvirus-like particles carrying repetitive copies of foreign antigens in Escherichia coli", <i>Bio/Tech.</i> (1993) 11:1166-1170	
		KORNREICH, et al., Swiss Prot accession number AGAL_HUMAN, January 1988	
		KREBBERS, et al., "Prospects and progress in the production of foreign proteins and peptides in plants", <i>Plant Protein Engineering</i> , Shewry, et al., Eds., Cambridge University Press, Cambridge (1992) pp. 316-324	
		MURRAY, "Lectin-specific targeting of lysosomal enzymes to reticuloendothelial cells", <i>Methods in Enzymology</i> (1987) 149:25, 39, 41-42	
		MURRAY, et al., "Production of Recombinant Human Glucocerebrosidase in Plants", Fed. of American Soc. for Experimental Biology, (April 1996) 10(6):a1126	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Sı	ubstitute for form 144	9B/PT	TO	Complete if Known		
				Application Number	10/602,219	
IN	IFORMATION D	ISC	LOSURE	Filing Date	6/23/2003	
	TATEMENT BY			First Named Inventor	TURPEN	
	(use as many sheets			Group Art Unit	1652	
				Examiner Name	Delia M. RAMIREZ	
Sheet	Sheet 3 of		3	Attorney Docket Number	LSBC-0087-CN09B	

1	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²				
		TAKAMATSU, et al., "Production of enkephalin in tobacco protoplasts using tobacco mosaic virus RNA vector", FEBS Lett. (1990) 269(1):73-76					
		TURPEN, et al., "Malarial epitopes expressed on the surface of recombinant tobacco mosaic virus", <i>Bio/Tech</i> . (1995) 13:53-57					
		YUSIBOV, et al., "Antigens produced in plants by infection with chimeric plant viruses immunize against rabies virus and HIV-1", <i>Proc. Natl. Acad. Sci. USA</i> (1997) 94:5784-5788					
:							

-		
Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.